BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25316501)

  • 21. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer.
    Mudduluru G; Medved F; Grobholz R; Jost C; Gruber A; Leupold JH; Post S; Jansen A; Colburn NH; Allgayer H
    Cancer; 2007 Oct; 110(8):1697-707. PubMed ID: 17849461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
    Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
    Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medullary thyroid carcinoma.
    Pacini F; Castagna MG; Cipri C; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions.
    Cappellesso R; Tinazzi A; Giurici T; Simonato F; Guzzardo V; Ventura L; Crescenzi M; Chiarelli S; Fassina A
    Cancer Cytopathol; 2014 Sep; 122(9):685-93. PubMed ID: 24888238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.
    Cordero-Barreal A; Caleiras E; López de Maturana E; Monteagudo M; Martínez-Montes ÁM; Letón R; Gil E; Álvarez-Escolá C; Regojo RM; Andía V; Marazuela M; Guadalix S; Calatayud M; Robles-Díaz L; Aguirre M; Cano JM; Díaz JÁ; Saavedra P; Lamas C; Azriel S; Sastre J; Aller J; Leandro-García LJ; Calsina B; Roldán-Romero JM; Santos M; Lanillos J; Cascón A; Rodríguez-Antona C; Robledo M; Montero-Conde C
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32791518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
    Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
    Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.
    Abraham D; Jackson N; Gundara JS; Zhao J; Gill AJ; Delbridge L; Robinson BG; Sidhu SB
    Clin Cancer Res; 2011 Jul; 17(14):4772-81. PubMed ID: 21622722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 4-MicroRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears.
    Fassina A; Cappellesso R; Simonato F; Siri M; Ventura L; Tosato F; Busund LT; Pelizzo MR; Fassan M
    Cancer Cytopathol; 2014 Apr; 122(4):274-81. PubMed ID: 24327568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.
    Cavedon E; Barollo S; Bertazza L; Pennelli G; Galuppini F; Watutantrige-Fernando S; Censi S; Iacobone M; Benna C; Vianello F; Zovato S; Nacamulli D; Mian C
    Int J Endocrinol; 2017; 2017():4915736. PubMed ID: 28676824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of miRNAs as diagnostic and prognostic biomarkers, and possible therapeutic targets in medullary thyroid cancers.
    Mondin A; Bertazza L; Barollo S; Pedron MC; Manso J; Piva I; Basso D; Merante Boschin I; Iacobone M; Pezzani R; Mian C; Censi S
    Front Endocrinol (Lausanne); 2023; 14():1151583. PubMed ID: 37361540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients.
    Shabani N; Sheikholeslami S; Paryan M; Zarif Yeganeh M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
    J Cell Physiol; 2020 Feb; 235(2):1366-1373. PubMed ID: 31297834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
    Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
    Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.
    Gallel P; Pallares J; Dolcet X; Llobet D; Eritja N; Santacana M; Yeramian A; Palomar-Asenjo V; Lagarda H; Mauricio D; Encinas M; Matias-Guiu X
    Hum Pathol; 2008 Jul; 39(7):994-1001. PubMed ID: 18508109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.